Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lorlatinib PK in Hepatic Impairment
NCT05224609Phase 1Completed
- Sponsor
- Pfizer
- Start
- Apr 2022
- Primary completion
- Aug 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of lorlatinib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Pfizer. Primary endpoints: Area Under the Curve From Time Zero to Extrapolated Infinite Time, Area Under the Curve From Time Zero to Last Quantifiable Concentration and 1 more. Started Apr 2022; status: completed.
02
Drugs
lorlatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05224609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05224609.